



RESEARCH ARTICLE

CLOSTRIDIUM DIFFICILE MOST COMMON HOSPITAL ACQUIRED INFECTION: REVIEW

Nishtha Singh^{1*}, Pratishtha Singh², Ritu Tiwari³ and Shraddha Singh³

¹Assistant Professor, T.S. Misra University, Microbiology; ²Senior Resident, Ram Manohar Lohia Institute, Psychiatry; ³Senior Resident, King George Medical University, Physiology; ³Professor, King George Medical University, Physiology

ARTICLE INFO

Article History:

Received 14th September, 2024
Received in revised form
27th October, 2024
Accepted 20th November, 2024
Published online 26th December, 2024

Key Words:

Clostridioides Difficile Infection; Drug-Resistant Pathogen, Super-Bug, Virulence.

*Corresponding author: Nishtha Singh

ABSTRACT

Clostridioides difficile is the most important cause of healthcare-associated diarrhoea. The high incidence and recurrence rates of *C. difficile* infection (CDI) is associated with high morbidity and mortality. Antibiotics targeting *C. difficile* bacteria are the first treatment choice. Recurrent CDI infection is due to antibiotics which disrupt the indigenous gut flora there by creating an environment that is favourable for its growth. Antibiotic-resistant strains of *C. difficile*, has increased the challenge of treating CDI. It has come among the five emerging resistant threats. The evolution of antibiotic resistance in *C. difficile* involves the acquisition of new resistance mechanisms, which can be shared among various bacterial species and different *C. difficile* strains within clinical and community settings. This review provides a summary of commonly used diagnostic tests and antibiotic treatment strategies for CDI. It aims to enhance our current understanding and pinpoint knowledge gaps in antimicrobial resistance mechanisms in *C. difficile*, with an emphasis on CDI therapies. This can be associated with the appearance of hypervirulent epidemic isolates of ribotype 027. The aim of this review article is to characterise *C. difficile* as a new member of the "superbug" family. Due to its worldwide spread, the lack of many treatment options and the high rates of both recurrence and mortality, *C. difficile* has emerged as a major concern for the healthcare system

Copyright©2024, Nishtha Singh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation: Nishtha Singh, Pratishtha Singh, Ritu Tiwari, Shraddha Singh. 2024. "Clostridium difficile most common hospital acquired infection: Review". *International Journal of Current Research*, 16, (12), 30892-30894.


INTRODUCTION

Clostridium difficile infection (CDI) occurs when there is a shift in the colonic microbial flora. This shift allows toxin-producing strains of the Gram-positive, spore-forming, anaerobic bacillus to over proliferate (1). Antibiotic exposure is the most important risk factor for CDI as its consumption results in a reduction in the population of non-pathogenic anaerobes that normally inhabit the gut providing protective immunity (2). *C. difficile* infections (CDIs) are known to be one of the most common nosocomial (hospital-acquired) infections which is frequently increasing morbidity and mortality in adult hospital patients (3). The clinical features of *C. difficile* infections (CDIs) can vary, ranging from the asymptomatic carriage and mild self-limiting diarrhoea. Sometimes it can cause severe and fatal pseudomembranous colitis. Clinical manifestations of CDI commonly include fever, leuko-cytosis, abdominal pain and profuse watery diarrhoea (4). CDI generally occurs from strains that produce two exotoxins, toxin A (*tcdA*) and toxin B (*tcdB*) (5), (6). A third toxin (*clostridium* binary toxin, CDT) has been identified in approximately 20% of *C. difficile* strains (7), (8), (9). Strains that produce CDT, such as PCR ribotype 027/North American pulse-field type 1, restriction endonuclease analysis type B1

strain (NAP1/B1/027 or RT-027), are often associated with severe disease and are known as hypervirulent strains (10).

LABORATORY DIAGNOSIS: The clinical picture of CDI is very heterogeneous, and ranges from the asymptomatic carrier state, mild or moderate diarrhea, to life-threatening fulminant colitis. Although the incubation period is not precisely defined, and some reports suggest 2–3 days, more recent studies demonstrate that the incubation period might be even longer than 3 days and is very individual-dependent. In the most severe clinical presentation of CDI, symptoms are life-threatening, and include significant dehydration, abdominal distension, hypo-albuminemia with peripheral edema, and subsequent circulatory shock. Diagnostic tests include nucleic acid amplification testing (NAAT), enzyme immunoassay (EIA), cell culture cytotoxicity assay, and selective anaerobic cultures. The 2017 Infectious Diseases Society of America (IDSA)/Society for Healthcare Epidemiology of America (SHEA) guidelines recommend testing patients with unexplained new-onset diarrhea with three or more unformed stools in 24 hours (11). According to European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidance, no single test is suitable as a stand-alone test confirming CDI. The best way to optimize

diagnosis of CDI is to combine two tests in algorithm. The first test should be a test with high negative predictive value (it can either be a GDH EIA or NAAT). The second test should be a test with a high positive predictive value (it is toxin A/B EIAs). If the first test is negative, it excludes CDI. If the first test is positive, the second test (toxin A/B EIAs) should be performed. If the second test is positive, it confirms CDI. If the second test is negative, the case needs to be clinically evaluated. If GDH EIA is positive, additional testing must be done to confirm the presence of a toxigenic strain. An EIA testing for toxins A and B should also be performed. It should be noted that EIA for toxins A and B have a high false-negative rate due to the large amount of toxin needed for a positive test (12). Radiography of the abdomen and pelvis is usually warranted in patients with severe colitis. Plain abdominal X-rays may show dilated bowels as well as classic signs of bowel edema and inflammation called "target signs" and "thumb printing" (13). For patients with primary infection of CDI, metronidazole should be considered over vancomycin or fidaxomicin for only the mildest cases (14). However, it is important to note that depending solely on molecular tests may result in overdiagnosis, unnecessary treatment and elevated healthcare costs associated with CDI Tox-/PCR+ patients showed a lower bacterial load, less antibiotic exposure and fewer complications compared to Tox+/PCR+ patients. The management of CDI primarily relies on three antibiotics: metronidazole, vancomycin and fidaxomicin, which are routinely employed in its treatment (15). Based on this knowledge, there are studies on intravenous administration of immunoglobulins as well as monoclonal antibodies that may be useful in both the treatment and prevention of CDI recurrences.



TREATMENT: The management of CDI primarily relies on three antibiotics: metronidazole, vancomycin and fidaxomicin, which are routinely employed in its treatment. Belonging to the macrocyclic lactones (macrolide) class of antimicrobial agents, fidaxomicin is unique in its narrow spectrum of antibacterial activity (16). Treatment should only be started in patients with CDI symptoms; presence of the *C. difficile* toxin without symptoms of the infection is not an indication for treatment. In 2014, the ESCMID guidelines were published in which two drugs metronidazole and vancomycin were the cornerstone of CDI treatment. Metronidazole was first-line drug in non-severe CDI, while vancomycin was the drug of choice for severe CDI (17). If there is high suspicion of CDI with a negative ELISA assay, it is reasonable to start empiric antibiotic therapy for CDI.

Other antibiotics that show activity against *C. difficile* include teicoplanin, tigecycline, bacitracin, and nitazoxanide. The role of probiotics in the treatment and prevention of CDI is completely unknown. There are studies on intravenous administration of immunoglobulins as well as monoclonal antibodies that may be useful in both the treatment and prevention of CDI recurrences (18). Bezlotoxumab (a monoclonal antibody that binds to *C. difficile* toxin B) was approved by the FDA in 2016 for prevention of recurrent CDI in patients with high risk of CDI recurrence (19). The fecal microbiota transplantation (FMT) procedure has been known for over 1000 years. The first report about fecal transplantation in patient with confirmed *C. difficile* infection was published in 1983 (20). Antibiotic withdrawal together with FMT have the highest rate of prevention of recurrent CDI among all therapeutic options (21).

CONCLUSION

Antibiotic resistance in *C. difficile* is a global concern, marked by a rise in multidrug resistance (MDR) and the emergence of novel, often more virulent, strains worldwide. The evolution of antibiotic resistance in *C. difficile* continues as it acquires new resistance-determining mechanisms. In addition to toxigenic strains, non-toxigenic *C. difficile* strains are gaining significance as a notable reservoir of antibiotic resistance. These strains, prevalent in the natural environment, can colonize both humans and animals, thereby playing a substantial role in disseminating antibiotic resistance. In this regard, continuous surveillance of antibiotic resistance in *C. difficile* isolates from patients is crucial for comprehending the epidemiology and evolution of *C. difficile*. Moreover, public health surveillance focusing on genomics is essential for understanding and addressing the MDR in *C. difficile*, given its high diversity, mobile resistome and the continual discovery of new resistance mechanisms. Along with monitoring antibiotic resistance over time, practicing antibiotic stewardship and judicious use of antimicrobial agents with minimal impact on beneficial gut bacteria are essential strategies to address the problem. Ongoing research into the resistance mechanisms of *C. difficile*, as well as the development of new antimicrobial agents effective against *C. difficile*, is imperative. Additionally, the pursuit of alternative therapies that boost the host immune response and support gut microbiota and its associated metabolites for CDI should be considered. Ultimately, an effective vaccine would be the most effective way of preventing CDI-associated morbidity and mortality. No FDA-approved *C. difficile* vaccine currently exists; however, clinical trials and research into the development of an effective vaccine against CDI are ongoing.

Author Contributions: All authors contributed equally in drafting manuscript.

Conflict of Interest: Authors have no conflict of interest.

REFERENCES

- Smits, W.K.; Lyras, D.; Lacy, D.B.; Wilcox, M.H.; Kuijper, E.J. *Clostridium difficile* Infection. *Nat. Rev. Dis. Primers* 2016, 2, 16020. (CrossRef)
- Kesavelu, D.; Jog, P. Current Understanding of Antibiotic-Associated Dysbiosis and Approaches for Its Management.

- Ther. Adv. Infect. Dis.* 2023, 10, 20499361231154443. (CrossRef) (PubMed)
- Guh AY, Mu Y, Winston LG, et al.: Trends in U.S. burden of *Clostridioides difficile* infection and outcomes. *N Engl J Med.* 2020, 382:1320-30. 10.1056/NEJMoa1910215
- McDonald, L.C.; Gerding, D.N.; Johnson, S.; Bakken, J.S.; Carroll, K.C.; Coffin, S.E.; Dubberke, E.R.; Garey, K.W.; Gould, C.V.; Kelly, C.; et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin. Infect. Dis.* 2018, 66, e1–e48. (CrossRef)
- Orrell, K.E.; Melnyk, R.A. Large *Clostridial* Toxins: Mechanisms and Roles in Disease. *Microbiol. Mol. Biol. Rev.* 2021, 85, e0006421. (CrossRef)
- Aktories, K.; Schwan, C.; Jank, T. *Clostridium difficile* Toxin Biology. *Annu. Rev. Microbiol.* 2017, 71, 281–307. (CrossRef) (PubMed)
- Aktories, K.; Schwan, C.; Jank, T. *Clostridium difficile* Toxin Biology. *Annu. Rev. Microbiol.* 2017, 71, 281–307. (CrossRef) (PubMed)
- Aktories, K.; Papatheodorou, P.; Schwan, C. Binary *Clostridium difficile* Toxin (CDT)—A Virulence Factor Disturbing the Cytoskeleton. *Anaerobe* 2018, 53, 21–29. (CrossRef)
- Martínez-Meléndez, A.; Cruz-López, F.; Morfin-Otero, R.; Maldonado-Garza, H.J.; Garza-González, E. An Update on *Clostridioides*
- Liu, C.; Monaghan, T.; Yadegar, A.; Louie, T.; Kao, D. Insights into the Evolving Epidemiology of *Clostridioides difficile* Infection and Treatment: A Global Perspective. *Antibiotics* 2023, 12, 1141. (CrossRef) *difficile* Binary Toxin. *Toxins* 2022, 14, 305. (CrossRef)
- Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, Stollman NH: ACG clinical guidelines: prevention, diagnosis, and treatment of *Clostridioides difficile* infections. *Am J Gastroenterol.* 2021, 116:1124-47. 10.14309/ajg.0000000000001278
- Crobach MJ, Baktash A, Duszenko N, Kuijper EJ: Diagnostic guidance for *C. difficile* infections. *Adv Exp Med Biol.* 2018, 1050:27-44. 10.1007/978-3-319-72799-8_3
- Johnson, S.; Lavergne, V.; Skinner, A.M.; Gonzales-Luna, A.J.; Garey, K.W.; Kelly, C.P.; Wilcox, M.H. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of *Clostridioides difficile* Infection in Adults. *Clin. Infect. Dis.* 2021, 73, 755–757. (CrossRef)
- Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA: Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in *Clostridium difficile* infections: a meta-analysis and indirect treatment comparison. *J Antimicrob Chemother.* 2014, 69:2892-900. 10.1093/jac/dku261
- van Prehn, J.; Reigadas, E.; Vogelzang, E.H.; Bouza, E.; Hristea, A.; Guery, B.; Krutova, M.; Norén, T.; Allerberger, F.; Coia, J.E.; et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 Update on the Treatment Guidance Document for *Clostridioides difficile* Infection in Adults. *Clin. Microbiol. Infect.* 2021, 27 (Suppl. S2), S1–S21.
- Zhanel, G.G.; Walkty, A.J.; Karlowsky, J.A. Fidaxomicin: A Novel Agent for the Treatment of *Clostridium difficile* Infection. *Can. J. Infect. Dis. Med. Microbiol.* 2015, 26, 305–312. (CrossRef)
- Debast SB, Bauer MP, Kuijper EJ, ESCMID (2014) European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for *Clostridium difficile* infection. *Clin Microbiol Infect* 20:1–26
- Mulligan ME, Miller SD, McFarland LV *et al* (1993) Elevated levels of serum immunoglobulins in asymptomatic carriers of *Clostridium difficile*. *Clin Infect Dis* 16:239–244
- Baker SJ, Chu DI: Physical, laboratory, radiographic, and endoscopic workup for *Clostridium difficile* colitis. *Clin Colon Rectal Surg.* 2020, 33:82-6. 10.1055/s-0039-3400474
20. Schwan A, Sjolín S, Trottestam U, Aronsson B (1983) Relapsing *Clostridium difficile* enterocolitis cured by rectal infusion of homologous faeces. *Lancet* 2:845
- Dutta SK, Girotra M, Garg S *et al.* (2014) Efficacy of combined jejunal and colonic fecal microbiota transplantation for recurrent *Clostridium difficile* infection. *Clin Gastroenterol Hepatol* 12: 1572–1576
